secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001641172-25-010377
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glucotrack Q1 net loss widens to $6.8M; cash $9.1M; on track for CBGM study Q3 2025
--------------------------------------------------------------------------------

- Net loss $6.8M vs $2.9M YoY; includes $3.4M non-cash derivative liability change.
- R&D expense $1.9M (down $0.2M); MG&A $1.6M (up $0.8M on legal/professional fees).
- Cash $9.1M at Mar 31, 2025 vs $5.6M at Dec 31, 2024; $6.4M from financing.
- First patients in Australian CBGM feasibility study expected Q3 2025; FDA IDE pilot study expected Q4 2025.
- First-in-human study met primary endpoint; no device-related serious adverse events.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000164117225010377/0001641172-25-010377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000164117225010377/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-010377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer